The eosinophil in health and disease: From bench to bedside and back

Clinical Reviews in Allergy and Immunology

Volumn 50, Issue 2, 2016, Pages 125-139

  Liao, Wei ^a   Long, Hai ^a   Chang, Christopher Chia Chi ^b   Lu, Qianjin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Asthma; Eosinophil; Eosinophilia; Epigenetics; Genetics; Hypereosinophilic syndrome; Inflammation

Indexed keywords

ADHESION RECEPTOR; ANTIGEN; CCAAT ENHANCER BINDING PROTEIN; CELL MARKER; CHEMOKINE RECEPTOR; COMPLEMENT RECEPTOR; CYTOKINE RECEPTOR; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHIL GRANULE PROTEIN; EOSINOPHIL PEROXIDASE; EOTAXIN; FC RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ANTIGEN 1; MAJOR BASIC PROTEIN; PATTERN RECOGNITION RECEPTOR; RECEPTOR; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MEMBRANE PROTEIN;

ANTIGEN PRESENTATION; ARTICLE; ASTHMA; CELL SURFACE; CYTOLOGY; DEGRANULATION; DISEASE ASSOCIATION; DISEASES; EOSINOPHIL; EOSINOPHILIA; EPIGENETICS; GENETIC REGULATION; GENETIC VARIABILITY; HEALTH; HUMAN; HYPEREOSINOPHILIA; HYPEREOSINOPHILIC SYNDROME; IMMUNOREGULATION; MAST CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; THYMUS; ANIMAL; DISEASE PREDISPOSITION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; IMMUNOMODULATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; TRANSLATIONAL RESEARCH;

ANIMALS; BIOMARKERS; DISEASE SUSCEPTIBILITY; EOSINOPHIL GRANULE PROTEINS; EOSINOPHILIA; EOSINOPHILS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; HUMANS; HYPEREOSINOPHILIC SYNDROME; IMMUNOMODULATION; MEMBRANE PROTEINS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84944710852     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-015-8507-6     Document Type: Article

References (161)

1. Rothenberg ME, Hogan SP (2006) The eosinophil. Annu Rev Immunol 24:147-174
2. Gleich GJ, Adolphson CR (1986) The eosinophilic leukocyte: structure and function. Adv Immunol 39:177-253
3. Hogan SP, Rosenberg HF, Moqbel R et al (2008) Eosinophils: biological properties and role in health and disease. Clin Exp Allergy 38:709-750
4. Yang YH, Chiang BL (2014) Novel approaches to food allergy. Clin Rev Allergy Immunol 46:250-257
5. Weinstock JV (2014) Do we need worms to promote immune health? Clin Rev Allergy Immunol 1-5. doi:10.1007/s12016-014-8458-3
6. Hansel TT, De Vries IJ, Iff T et al (1991) An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J Immunol Methods 145:105-110
7. Hansel TT, De Vries IJ, Carballido JM et al (1992) Induction and function of eosinophil intercellular adhesion molecule-1 and HLA-DR. J Immunol 149:2130-2136
8. Chu VT, Frohlich A, Steinhauser G et al (2011) Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol 12:151-159
9. Wu D, Molofsky AB, Liang HE et al (2011) Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 332:243-247
10. Samoszuk M (1997) Eosinophils and human cancer. Histol Histopathol 12:807-812
11. Meleg-Smith S, Gauthier PM (2005) Abundance of interstitial eosinophils in renal allografts is associated with vascular rejection. Transplantation 79:444-450
12. Trull AK, Akhlaghi F, Charman SC et al (2004) Immunosuppression, eotaxin and the diagnostic changes in eosinophils that precede early acute heart allograft rejection. Transpl Immunol 12:159-166
13. Hamann KJ, Barker RL, Ten RM, Gleich GJ (1991) The molecular biology of eosinophil granule proteins. Int Arch Allergy Appl Immunol 94:202-209
14. Lehrer RI, Szklarek D, Barton A, Ganz T, Hamann KJ, Gleich GJ (1989) Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. J Immunol 142:4428-4434
15. Gleich GJ, Loegering DA, Bell MP, Checkel JL, Ackerman SJ, McKean DJ (1986) Biochemical and functional similarities between human eosinophil-derived neurotoxin and eosinophil cationic protein: homology with ribonuclease. Proc Natl Acad Sci U S A 83:3146-3150
16. Young JD, Peterson CG, Venge P, Cohn ZA (1986)Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature 321:613-616
17. Venge P, Bystrom J, Carlson M et al (1999) Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy 29:1172-1186
18. O’Donnell MC, Ackerman SJ, Gleich GJ, Thomas LL (1983) Activation of basophil and mast cell histamine release by eosinophil granule major basic protein. J Exp Med 157:1981-1991
19. Wasmoen TL, Bell MP, Loegering DA, Gleich GJ, Prendergast FG, McKean DJ (1988) Biochemical and amino acid sequence analysis of human eosinophil granule major basic protein. J Biol Chem 263:12559-12563
20. Agosti JM, Altman LC, Ayars GH, Loegering DA, Gleich GJ, Klebanoff SJ (1987) The injurious effect of eosinophil peroxidase, hydrogen peroxide, and halides on pneumocytes in vitro. J Allergy Clin Immunol 79:496-504
21. MacPherson JC, Comhair SA, Erzurum SC et al (2001) Eosinophils are a major source of nitric oxide-derived oxidants in severe asthma: characterization of pathways available to eosinophils for generating reactive nitrogen species. J Immunol 166: 5763-5772
22. Wu W, Chen Y, Hazen SL (1999) Eosinophil peroxidase nitrates protein tyrosyl residues. Implications for oxidative damage by nitrating intermediates in eosinophilic inflammatory disorders. J Biol Chem 274:25933-25944
23. Lacy P, Stow JL (2011) Cytokine release from innate immune cells: association with diverse membrane trafficking pathways. Blood 118:9-18
24. Spencer LA, Melo RC, Perez SA, Bafford SP, Dvorak AM, Weller PF (2006) Cytokine receptor-mediated trafficking of preformed IL-4 in eosinophils identifies an innate immune mechanism of cytokine secretion. Proc Natl Acad Sci U S A 103:3333-3338
25. Rosenberg HF, Dyer KD, Foster PS (2013) Eosinophils: changing perspectives in health and disease. Nat Rev Immunol 13:9-22
26. Shamri R, Xenakis JJ, Spencer LA (2011) Eosinophils in innate immunity: an evolving story. Cell Tissue Res 343:57-83
27. Sriramarao P, von Andrian UH, Butcher EC, Bourdon MA, Broide DH (1994) L-selectin and very late antigen-4 integrin promote eosinophil rolling at physiological shear rates in vivo. J Immunol 153:4238-4246
28. Berg EL, McEvoy LM, Berlin C, Bargatze RF, Butcher EC (1993) L-selectin-mediated lymphocyte rolling on MAdCAM-1. Nature 366:695-698
29. Symon FA, Lawrence MB, Williamson ML, Walsh GM, Watson SR, Wardlaw AJ (1996) Functional and structural characterization of the eosinophil P-selectin ligand. J Immunol 157:1711-1719
30. Forbes E, Hulett M, Ahrens R et al (2006) ICAM-1-dependent pathways regulate colonic eosinophilic inflammation. J Leukoc Biol 80:330-341
31. Bochner BS, Schleimer RP (2001) Mast cells, basophils, and eosinophils: distinct but overlapping pathways for recruitment. Immunol Rev 179:5-15
32. Wang H, Rudd CE (2008) SKAP-55, SKAP-55-related and ADAP adaptors modulate integrin-mediated immune-cell adhesion. Trends Cell Biol 18:486-493
33. Mishra A, Hogan SP, Brandt EB et al (2002) Enterocyte expression of the eotaxin and interleukin-5 transgenes induces compartmentalized dysregulation of eosinophil trafficking. J Biol Chem 277:4406-4412
34. Artis D, Humphreys NE, Potten CS et al (2000) Beta7 integrindeficient mice: delayed leukocyte recruitment and attenuated protective immunity in the small intestine during enteric helminth infection. Eur J Immunol 30:1656-1664
35. Nakajima H, Sano H, Nishimura T, Yoshida S, Iwamoto I (1994) Role of vascular cell adhesion molecule 1/very late activation antigen 4 and intercellular adhesion molecule 1/lymphocyte function-associated antigen 1 interactions in antigen-induced eosinophil and T cell recruitment into the tissue. J Exp Med 179: 1145-1154
36. Pretolani M, Ruffie C, Lapa e Silva JR, Joseph D, Lobb RR, Vargaftig BB (1994) Antibody to very late activation antigen 4 prevents antigen-induced bronchial hyperreactivity and cellular infiltration in the guinea pig airways. J Exp Med 180:795-805
37. Okigami H, Takeshita K, Tajimi M et al (2007) Inhibition of eosinophilia in vivo by a small molecule inhibitor of very late antigen (VLA)-4. Eur J Pharmacol 559:202-209
38. Wang H, Tan X, Chang H, Huang W, Gonzalez-Crussi F, Hsueh W(1999) Platelet-activating factor receptor mRNA is localized in eosinophils and epithelial cells in rat small intestine: regulation by dexamethasone and gut flora. Immunology 97:447-454
39. Fujii M, Tanaka H, Abe S (2005) Interferon-gamma up-regulates expression of cysteinyl leukotriene type 2 receptors on eosinophils in asthmatic patients. Chest 128:3148-3155
40. Zinchuk O, Fukushima A, Zinchuk V, Fukata K, Ueno H (2005) Direct action of platelet activating factor (PAF) induces eosinophil accumulation and enhances expression of PAF receptors in conjunctivitis. Mol Vis 11:114-123
41. Thivierge M, Doty M, Johnson J, Stankova J, Rola-Pleszczynski M (2000) IL-5 up-regulates cysteinyl leukotriene 1 receptor expression in HL-60 cells differentiated into eosinophils. J Immunol 165:5221-5226
42. Hirai H, Tanaka K, Yoshie O et al (2001) Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 193:255-261
43. Sugimoto H, Shichijo M, Iino T et al (2003) An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro. J Pharmacol Exp Ther 305:347-352
44. Barnes N, Pavord I, Chuchalin A et al (2012) A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy 42: 38-48
45. Elsner J, Dulkys Y, Gupta S et al (2005) Differential pattern of CCR1 internalization in human eosinophils: prolonged internalization by CCL5 in contrast to CCL3. Allergy 60:1386-1393
46. Phillips RM, Stubbs VE, Henson MR, Williams TJ, Pease JE, Sabroe I (2003) Variations in eosinophil chemokine responses: an investigation ofCCR1 and CCR3 function, expression in atopy, and identification of a functional CCR1 promoter. J Immunol 170: 6190-6201
47. Gong L, Wilhelm RS (2009) CCR3 antagonists: a survey of the patent literature. Expert Opin Ther Pat 19:1109-1132
48. Sullivan SK, McGrath DA, Liao F, Boehme SA, Farber JM, Bacon KB (1999) MIP-3alpha induces human eosinophil migration and activation of the mitogen-activated protein kinases (p42/ p44 MAPK). J Leukoc Biol 66:674-682
49. Nagase H, Miyamasu M, Yamaguchi M et al (2000) Glucocorticoids preferentially upregulate functional CXCR4 expression in eosinophils. J Allergy Clin Immunol 106:1132-1139
50. Oliveira SH, Lira S, Martinez AC, Wiekowski M, Sullivan L, Lukacs NW (2002) Increased responsiveness of murine eosinophils to MIP-1beta (CCL4) and TCA-3 (CCL1) is mediated by their specific receptors, CCR5 and CCR8. J Leukoc Biol 71: 1019-1025
51. Rothenberg ME, Pomerantz JL, Owen WF Jr et al (1988) Characterization of a human eosinophil proteoglycan, and augmentation of its biosynthesis and size by interleukin 3, interleukin 5, and granulocyte/macrophage colony stimulating factor. J Biol Chem 263:13901-13908
52. Wechsler ME, Fulkerson PC, Bochner BS et al (2012) Novel targeted therapies for eosinophilic disorders. J Allergy Clin Immunol 130:563-571
53. Zeck-Kapp G, Czech W, Kapp A (1994) TNF alpha-induced activation of eosinophil oxidative metabolism and morphology— comparison with IL-5. Exp Dermatol 3:176-188
54. Kvarnhammar AM, Cardell LO (2012) Pattern-recognition receptors in human eosinophils. Immunology 136:11-20
55. Wong CK, Cheung PF, Ip WK, Lam CW (2007) Intracellular signaling mechanisms regulating toll-like receptor-mediated activation of eosinophils. Am J Respir Cell Mol Biol 37:85-96
56. Nagase H, Okugawa S, Ota Y et al (2003) Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. J Immunol 171:3977-3982
57. Walsh GM, Hartnell A, Moqbel R et al (1990) Receptor expression and functional status of cultured human eosinophils derived from umbilical cord blood mononuclear cells. Blood 76:105-111
58. Giembycz MA, Lindsay MA (1999) Pharmacology of the eosinophil. Pharmacol Rev 51:213-340
59. Koenderman L, Kuijpers TW, Blom M, Tool AT, Roos D, Verhoeven AJ (1991) Characteristics of CR3-mediated aggregation in human eosinophils: effect of priming by platelet-activating factor. J Allergy Clin Immunol 87:947-954
60. Kita H, Gleich GJ (1997) Eosinophils and IgE receptors: a continuing controversy. Blood 89:3497-3501
61. Seminario MC, Saini SS, MacGlashan DW Jr, Bochner BS (1999) Intracellular expression and release of Fc epsilon RI alpha by human eosinophils. J Immunol 162:6893-6900
62. Kita H, Kaneko M, Bartemes KR et al (1999) Does IgE bind to and activate eosinophils from patients with allergy? J Immunol 162:6901-6911
63. Ying S, Barata LT, Meng Q et al (1998) High-affinity immunoglobulin E receptor (Fc epsilon RI)-bearing eosinophils, mast cells, macrophages and Langerhans’ cells in allergen-induced late-phase cutaneous reactions in atopic subjects. Immunology 93:281-288
64. Lucey DR, Nicholson-Weller A, Weller PF (1989) Mature human eosinophils have the capacity to express HLA-DR. Proc NatlAcad Sci U S A 86:1348-1351
65. Mawhorter SD, Kazura JW, Boom WH (1994) Human eosinophils as antigen-presenting cells: relative efficiency for superantigen-and antigen-induced CD4+ T-cell proliferation. Immunology 81:584-591
66. Celestin J, Rotschke O, Falk K et al (2001) IL-3 induces B7.2 (CD86) expression and costimulatory activity in human eosinophils. J Immunol 167:6097-6104
67. Shi HZ, Humbles A, Gerard C, Jin Z, Weller PF (2000) Lymph node trafficking and antigen presentation by endobronchial eosinophils. J Clin Invest 105:945-953
68. Duez C, Dakhama A, Tomkinson A et al (2004) Migration and accumulation of eosinophils toward regional lymph nodes after airway allergen challenge. J Allergy Clin Immunol 114:820-825
69. Tamura N, Ishii N, Nakazawa M et al (1996) Requirement of CD80 and CD86 molecules for antigen presentation by eosinophils. Scand J Immunol 44:229-238
70. Wang HB, Ghiran I, Matthaei K, Weller PF (2007) Airway eosinophils: allergic inflammation recruited professional antigenpresenting cells. J Immunol 179:7585-7592
71. MacKenzie JR, Mattes J, Dent LA, Foster PS (2001) Eosinophils promote allergic disease of the lung by regulating CD4(+) Th2 lymphocyte function. J Immunol 167:3146-3155
72. Padigel UM, Hess JA, Lee JJ et al (2007) Eosinophils act as antigen-presenting cells to induce immunity to Strongyloides stercoralis in mice. J Infect Dis 196:1844-1851
73. van Rijt LS, Vos N, Hijdra D, de Vries VC, Hoogsteden HC, Lambrecht BN (2003) Airway eosinophils accumulate in the mediastinal lymph nodes but lack antigen-presenting potential for naive T cells. J Immunol 171:3372-3378
74. Zheutlin LM, Ackerman SJ, Gleich GJ, Thomas LL (1984) Stimulation of basophil and rat mast cell histamine release by eosinophil granule-derived cationic proteins. J Immunol 133: 2180-2185
75. Piliponsky AM, Gleich GJ, Bar I, Levi-Schaffer F (2002) Effects of eosinophils on mast cells: a new pathway for the perpetuation of allergic inflammation. Mol Immunol 38:1369
76. Wong CK, Ng SS, Lun SW, Cao J, Lam CW (2009) Signalling mechanisms regulating the activation of human eosinophils by mast-cell-derived chymase: implications for mast cell-eosinophil interaction in allergic inflammation. Immunology 126:579-587
77. Matsuba-Kitamura S, Yoshimoto T, Yasuda K et al (2010) Contribution of IL-33 to induction and augmentation of experimental allergic conjunctivitis. Int Immunol 22:479-489
78. Solomon A, Aloe L, Pe’er J et al (1998) Nerve growth factor is preformed in and activates human peripheral blood eosinophils. J Allergy Clin Immunol 102:454-460
79. Bullock ED, Johnson EM Jr (1996) Nerve growth factor induces the expression of certain cytokine genes and bcl-2 in mast cells. Potential role in survival promotion. J Biol Chem 271:27500-27508
80. Horigome K, Bullock ED, Johnson EM Jr (1994) Effects of nerve growth factor on rat peritoneal mast cells. Survival promotion and immediate-early gene induction. J Biol Chem 269:2695-2702
81. Throsby M, Herbelin A, Pleau JM, Dardenne M (2000) CD11c+ eosinophils in the murine thymus: developmental regulation and recruitment upon MHC class I-restricted thymocyte deletion. J Immunol 165:1965-1975
82. Tulic MK, Sly PD, Andrews D et al (2009) Thymic indoleamine 2, 3-dioxygenase-positive eosinophils in young children: potential role in maturation of the naive immune system. Am J Pathol 175:2043-2052
83. Matthews AN, Friend DS, Zimmermann N et al (1998) Eotaxin is required for the baseline level of tissue eosinophils. Proc Natl Acad Sci U S A 95:6273-6278
84. Fulkerson PC, Fischetti CA, McBride ML, Hassman LM, Hogan SP, Rothenberg ME (2006) A central regulatory role for eosinophils and the eotaxin/CCR3 axis in chronic experimental allergic airway inflammation. Proc Natl Acad Sci U S A 103:16418-16423
85. Kim HJ, Alonzo ES, Dorothee G, Pollard JW, Sant’Angelo DB (2010) Selective depletion of eosinophils or neutrophils in mice impacts the efficiency of apoptotic cell clearance in the thymus. PLoS One 5, e11439
86. Sferruzzi-Perri AN, Robertson SA, Dent LA (2003) Interleukin-5 transgene expression and eosinophilia are associated with retarded mammary gland development in mice. Biol Reprod 69:224-233
87. Robertson SA, Mau VJ, Young IG, Matthaei KI (2000) Uterine eosinophils and reproductive performance in interleukin 5-deficient mice. J Reprod Fertil 120:423-432
88. Zhang J, Lathbury LJ, Salamonsen LA (2000) Expression of the chemokine eotaxin and its receptor, CCR3, in human endometrium. Biol Reprod 62:404-411
89. Gouon-Evans V, Pollard JW (2001) Eotaxin is required for eosinophil homing into the stroma of the pubertal and cycling uterus. Endocrinology 142:4515-4521
90. Gouon-Evans V, Lin EY, Pollard JW (2002) Requirement of macrophages and eosinophils and their cytokines/chemokines for mammary gland development. Breast Cancer Res 4:155-164
91. Knudsen UB, Uldbjerg N, Rechberger T, Fredens K (1997) Eosinophils in human cervical ripening. Eur J Obstet Gynecol Reprod Biol 72:165-168
92. Timmons BC, Fairhurst AM, Mahendroo MS (2009) Temporal changes in myeloid cells in the cervix during pregnancy and parturition. J Immunol 182:2700-2707
93. Robertson SA, Mau VJ, Hudson SN, Tremellen KP (1997) Cytokine-leukocyte networks and the establishment of pregnancy. Am J Reprod Immunol 37:438-442
94. De M, Choudhuri R, Wood GW (1991) Determination of the number and distribution of macrophages, lymphocytes, and granulocytes in the mouse uterus from mating through implantation. J Leukoc Biol 50:252-262
95. Maddox DE, Kephart GM, Coulam CB, Butterfield JH, Benirschke K, Gleich GJ (1984) Localization of a molecule immunochemically similar to eosinophil major basic protein in human placenta. J Exp Med 160:29-41
96. Wagner JM, Hustin J, Bonno M, Kephart GM, Gurian KV, Gleich GJ (1994) Pregnancy-associated major basic protein: deposition of protein and expression of mRNA at the maternal-fetal junction in early and late gestation. Placenta 15:625-640
97. Gouon-Evans V, Rothenberg ME, Pollard JW (2000) Postnatal mammary gland development requires macrophages and eosinophils. Development 127:2269-2282
98. Colbert DC, McGarry MP, O’Neill K, Lee NA, Lee JJ (2005) Decreased size and survival of weanling mice in litters of IL-5-/-mice are a consequence of the IL-5 deficiency in nursing dams. Contemp Top Lab Anim Sci 44:53-55
99. Boyce JA, Friend D, Matsumoto R, Austen KF, Owen WF (1995) Differentiation in vitro of hybrid eosinophil/basophil granulocytes: autocrine function of an eosinophil developmental intermediate. J Exp Med 182:49-57
100. Nerlov C, Graf T (1998) PU.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors. Genes Dev 12: 2403-2412
101. McNagny K, Graf T (2002) Making eosinophils through subtle shifts in transcription factor expression. J Exp Med 195:F43-F47
102. Yu C, Cantor AB, Yang H et al (2002) Targeted deletion of a highaffinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med 195: 1387-1395
103. Hirasawa R, Shimizu R, Takahashi S et al (2002) Essential and instructive roles of GATA factors in eosinophil development. J Exp Med 195:1379-1386
104. Iwasaki H, Mizuno S, Mayfield R et al (2005) Identification of eosinophil lineage-committed progenitors in themurine bonemarrow. J Exp Med 201:1891-1897
105. Du J, Stankiewicz MJ, Liu Y et al (2002) Novel combinatorial interactions of GATA-1, PU.1, and C/EBPepsilon isoforms regulate transcription of the gene encoding eosinophil granule major basic protein. J Biol Chem 277:43481-43494
106. Zimmermann N, Daugherty BL, Kavanaugh JL, El-Awar FY, Moulton EA, Rothenberg ME (2000) Analysis of the CC chemokine receptor 3 gene reveals a complex 5′ exon organization, a functional role for untranslated exon 1, and a broadly active promoter with eosinophil-selective elements. Blood 96:2346-2354
107. Nerlov C, McNagny KM, Doderlein G, Kowenz-Leutz E, Graf T (1998) Distinct C/EBP functions are required for eosinophil lineage commitment and maturation. Genes Dev 12:2413-2423
108. Bedi R, Du J, Sharma AK, Gomes I, Ackerman SJ (2009) Human C/EBP-epsilon activator and repressor isoforms differentially reprogram myeloid lineage commitment and differentiation. Blood 113:317-327
109. DeKoter RP, Singh H (2000) Regulation of B lymphocyte and macrophage development by graded expression of PU.1. Science 288:1439-1441
110. Walsh JC, DeKoter RP, Lee HJ et al (2002) Cooperative and antagonistic interplay between PU.1 andGATA-2 in the specification of myeloid cell fates. Immunity 17:665-676
111. Vadas M, Lopez A, Gamble J et al (1994) Cytokines and allergy. J Allergy Clin Immunol 94:1289-1293
112. Sanderson CJ (1992) Interleukin-5, eosinophils, and disease. Blood 79:3101-3109
113. Lee JJ, McGarry MP, Farmer SC et al (1997) Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma. J Exp Med 185:2143-2156
114. Owen WF, Rothenberg ME, Petersen J et al (1989) Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome. J Exp Med 170: 343-348
115. Collins PD, Marleau S, Griffiths-Johnson DA, Jose PJ, Williams TJ (1995) Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med 182:1169-1174
116. Leckie MJ, ten Brinke A, Khan J et al (2000) Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356:2144-2148
117. Kips JC, O’Connor BJ, Langley SJ et al (2003) Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 167:1655-1659
118. Iikura M, Hojo M, Sugiyama H (2014) Glucocorticoids and mepolizumab in eosinophilic asthma. N Engl J Med 371:2433-2434
119. Walsh GM (2009) Mepolizumab and eosinophil-mediated disease. Curr Med Chem 16:4774-4778
120. Castro M, Wenzel SE, Bleecker ER et al (2014) Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2:879-890
121. Allakhverdi Z, Allam M, Guimond A et al (2006) Multitargeted approach using antisense oligonucleotides for the treatment of asthma. Ann N YAcad Sci 1082:62-73
122. Wong CK, Lau KM, Chan IH et al (2013) MicroRNA-21* regulates the prosurvival effect of GM-CSF on human eosinophils. Immunobiology 218:255-262
123. Lu TX, Lim EJ, Besse JA et al (2013) MiR-223 deficiency increases eosinophil progenitor proliferation. J Immunol 190:1576-1582
124. Hackanson B, Bennett KL, Brena RM et al (2008) Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia. Cancer Res 68:3142-3151
125. Perrotti D, Cesi V, Trotta R et al (2002) BCR-ABL suppresses C/ EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet 30:48-58
126. Eiring AM, Harb JG, Neviani P et al (2010) miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation ofmRNA translation in leukemic blasts. Cell 140:652-665
127. Radomska HS, Basseres DS, Zheng R et al (2006) Block of C/ EBP alpha function by phosphorylation in acutemyeloid leukemia with FLT3 activating mutations. J Exp Med 203:371-381
128. Wu CJ, Yang CY, Chen YH, Chen CM, Chen LC, Kuo ML (2013) The DNA methylation inhibitor 5-azacytidine increases regulatory T cells and alleviates airway inflammation in ovalbuminsensitized mice. Int Arch Allergy Immunol 160:356-364
129. Sun Q, Yang X, Zhong B et al (2012) Upregulated protein arginine methyltransferase 1 by IL-4 increases eotaxin-1 expression in airway epithelial cells and participates in antigen-induced pulmonary inflammation in rats. J Immunol 188:3506-3512
130. Nishioka C, Ikezoe T, Yang J, Yokoyama A (2010) Long-term exposure of leukemia cells to multi-targeted tyrosine kinase inhibitor induces activations of AKT, ERK and STAT5 signaling via epigenetic silencing of the PTEN gene. Leukemia 24:1631-1640
131. Gotlib J (2014) World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management. Am J Hematol 89:325-337
132. Long H, Zhang G, Wang L, Lu Q (2015) Eosinophilic skin diseases: a comprehensive review. Clin Rev Allergy Immunol 1-25. doi:10.1007/s12016-015-8485-8
133. Hardy WR, Anderson RE (1968) The hypereosinophilic syndromes. Ann Intern Med 68:1220-1229
134. Simon HU, Rothenberg ME, Bochner BS et al (2010) Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 126:45-49
135. Cogan E, Roufosse F (2012) Clinical management of the hypereosinophilic syndromes. Expert Rev Hematol 5:275-289
136. Chusid MJ, Dale DC, West BC, Wolff SM (1975) The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 54:1-27
137. Klion AD, Bochner BS, Gleich GJ et al (2006) Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 117:1292-1302
138. Valent P, Klion AD, Horny HP et al (2012) Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 130:607-612
139. Roufosse F, Goldman M, Cogan E (2006) Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants. Semin Respir Crit Care Med 27:158-170
140. Klion AD (2005) Recent advances in the diagnosis and treatment of hypereosinophilic syndromes. Hematol Am Soc Hematol Educ Prog 1:209-214
141. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH (2002) Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359:1577-1578
142. Cools J, DeAngelo DJ, Gotlib J et al (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201-1214
143. Stone RM, Gilliland DG, Klion AD (2004) Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome. Semin Oncol 31:12-17
144. Pardanani A, Ketterling RP, Li CY et al (2006) FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 30:965-970
145. Ogbogu PU, Bochner BS, Butterfield JH et al (2009) Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 124:1319-1325, e1313
146. Curtis CE, Grand FH, Musto P et al (2007) Two novel imatinibresponsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Br J Haematol 138:77-81
147. Bain BJ (2004) Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am J Hematol 77:82-85
148. Roufosse F, Cogan E, Goldman M (2007) Lymphocytic variant hypereosinophilic syndromes. Immunol Allergy Clin North Am 27:389-413
149. Kahn JE, Bletry O, Guillevin L (2008) Hypereosinophilic syndromes. Best Pract Res Clin Rheumatol 22:863-882
150. Brugnoni D, Airo P, Rossi G et al (1996) A case of hypereosinophilic syndrome is associated with the expansion of a CD3-CD4+ T-cell population able to secrete large amounts of interleukin-5. Blood 87:1416-1422
151. Cogan E, Schandene L, Crusiaux A, Cochaux P, Velu T, Goldman M (1994) Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med 330: 535-538
152. Lopez AF, Sanderson CJ, Gamble JR, Campbell HD, Young IG, Vadas MA (1988) Recombinant human interleukin 5 is a selective activator of human eosinophil function. J Exp Med 167:219-224
153. Corren J (2012) Inhibition of interleukin-5 for the treatment of eosinophilic diseases. Discov Med 13:305-312
154. Simon HU, Plotz SG, Dummer R, Blaser K (1999) Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 341:1112-1120
155. Vassina EM, Yousefi S, Simon D, Zwicky C, Conus S, Simon HU (2006) cIAP-2 and survivin contribute to cytokine-mediated delayed eosinophil apoptosis. Eur J Immunol 36:1975-1984
156. Klion A (2009) Hypereosinophilic syndrome: current approach to diagnosis and treatment. Annu Rev Med 60:293-306
157. Rioux JD, Stone VA, Daly MJ et al (1998) Familial eosinophilia maps to the cytokine gene cluster on human chromosomal region 5q31-q33. Am J Hum Genet 63:1086-1094
158. Klion AD, Law MA, Riemenschneider W et al (2004) Familial eosinophilia: a benign disorder? Blood 103:4050-4055
159. Sriaroon P, Ballow M (2014) Biological modulators in eosinophilic diseases. Clin Rev Allergy Immunol 1-21. doi:10.1007/s12016-014-8444-9
160. Kopf M, Brombacher F, Hodgkin PD et al (1996) IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity 4:15-24
161. Yoshida T, Ikuta K, Sugaya H et al (1996) Defective B-1 cell development and impaired immunity against Angiostrongylus cantonensis in IL-5R alpha-deficient mice. Immunity 4:483-494